Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BoneGlyc: Vildagliptin vs Gliclazide MR in Postmenopausal T2DM
NCT01679899Phase 4Completed
- Sponsor
- Centro de Diabetes Curitiba
- Start
- Dec 2012
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Centro de Diabetes Curitiba. Primary endpoint: Markers of bone remodeling at 6 months. Started Dec 2012; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01679899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01679899.